Abstract: Nosocomial infections caused by fungi have increased greatly in recent years, mainly due to the rising number of immunocompromised patients. However, the available antifungal therapeutic arsenal is limited, and the development of new drugs has been slow. Therefore, the search for alternative drugs with low resistance rates and fewer side effects remains a major challenge. Plants produce a variety of medicinal components that can inhibit pathogen growth. Studies of plant species have been conducted to evaluate the characteristics of natural drug products, including their sustainability, affordability, and antimicrobial activity. A considerable number of studies of medicinal plants and alternative compounds, such as secondary metabolites, phenolic compounds, essential oils and extracts, have been performed. Thus, this review discusses the history of the antifungal arsenal, surveys natural products with potential antifungal activity, discusses strategies to develop derivatives of natural products, and presents perspectives on the development of novel antifungal drug candidates.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Negri, M.; Salci, T.P.; Shinobu-Mesquita, C.S.; Capoci, I.R.G.; Svidzinski, T.I.E.; Kioshima, E.S. Early State Research on Antifungal Natural Products. Molecules 2014, 19, 2925-2956.
Negri M, Salci TP, Shinobu-Mesquita CS, Capoci IRG, Svidzinski TIE, Kioshima ES. Early State Research on Antifungal Natural Products. Molecules. 2014; 19(3):2925-2956.
Negri, Melyssa; Salci, Tânia P.; Shinobu-Mesquita, Cristiane S.; Capoci, Isis R.G.; Svidzinski, Terezinha I.E.; Kioshima, Erika S. 2014. "Early State Research on Antifungal Natural Products." Molecules 19, no. 3: 2925-2956.